Search | Nursing VHL Search Portal

1.

Oncolytic Virotherapy and the Tumor Microenvironment.

Berkey, Sara E; Thorne, Steve H; Bartlett, David L.

Adv Exp Med Biol ; 1036: 157-172, 2017.

Article in English | MEDLINE | ID: mdl-29275471

2.

Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.

Sampath, Padma; Li, Jun; Hou, Weizhou; Chen, Hannah; Bartlett, David L; Thorne, Steve H.

Mol Ther ; 21(3): 620-8, 2013 Mar.

Article in English | MEDLINE | ID: mdl-23229093

3.

Virus fuels NK cell killing of leukemia.

Thorne, Steve H.

Blood ; 127(21): 2509, 2016 05 26.

Article in English | MEDLINE | ID: mdl-27231392

4.

Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases.

Reeves, Patrick M; Smith, Scott K; Olson, Victoria A; Thorne, Steve H; Bornmann, William; Damon, Inger K; Kalman, Daniel.

J Virol ; 85(1): 21-31, 2011 Jan.

Article in English | MEDLINE | ID: mdl-20962097

5.

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

Li, Jun; O'Malley, Mark; Urban, Julie; Sampath, Padma; Guo, Z Sheng; Kalinski, Pawel; Thorne, Steve H; Bartlett, David L.

Mol Ther ; 19(4): 650-7, 2011 Apr.

Article in English | MEDLINE | ID: mdl-21266959

6.

Differential biodistribution of oncolytic poxvirus administered systemically in an autochthonous model of hepatocellular carcinoma.

Baril, Patrick; Touchefeu, Yann; Cany, Jeannette; Cherel, Yan; Thorne, Steve H; Tran, Lucile; Conchon, Sophie; Vassaux, Georges.

J Gene Med ; 13(12): 692-701, 2011 Dec.

Article in English | MEDLINE | ID: mdl-22028274

7.

The initial phase of an immune response functions to activate regulatory T cells.

O'Gorman, William E; Dooms, Hans; Thorne, Steve H; Kuswanto, Wilson F; Simonds, Erin F; Krutzik, Peter O; Nolan, Garry P; Abbas, Abul K.

J Immunol ; 183(1): 332-9, 2009 Jul 01.

Article in English | MEDLINE | ID: mdl-19542444

8.

Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters.

Dubikovskaya, Elena A; Thorne, Steve H; Pillow, Thomas H; Contag, Christopher H; Wender, Paul A.

Proc Natl Acad Sci U S A ; 105(34): 12128-33, 2008 Aug 26.

Article in English | MEDLINE | ID: mdl-18713866

9.

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.

Thorne, Steve H; Hwang, Tae-Ho H; O'Gorman, William E; Bartlett, David L; Sei, Shizuko; Kanji, Femina; Brown, Christopher; Werier, Joel; Cho, Jin-Han; Lee, Dong-Ewon; Wang, Yaohe; Bell, John; Kirn, David H.

J Clin Invest ; 117(11): 3350-8, 2007 Nov.

Article in English | MEDLINE | ID: mdl-17965776

10.

Enhancing biological therapy through conditional regulation of protein stability.

Thorne, Steve H.

Expert Rev Mol Med ; 12: e2, 2010 Jan 12.

Article in English | MEDLINE | ID: mdl-20064281

11.

Role of nitric oxide in Salmonella typhimurium-mediated cancer cell killing.

Barak, Yoram; Schreiber, Frank; Thorne, Steve H; Contag, Christopher H; Debeer, Dirk; Matin, A.

BMC Cancer ; 10: 146, 2010 Apr 17.

Article in English | MEDLINE | ID: mdl-20398414

12.

Giving oncolytic vaccinia virus more BiTE.

Albelda, Steven M; Thorne, Steve H.

Mol Ther ; 22(1): 6-8, 2014 Jan.

Article in English | MEDLINE | ID: mdl-24384909

13.

CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy.

Thorne, Steve H; Barak, Yoram; Liang, Wenchuan; Bachmann, Michael H; Rao, Jianghong; Contag, Christopher H; Matin, A.

Mol Cancer Ther ; 8(2): 333-41, 2009 Feb.

Article in English | MEDLINE | ID: mdl-19190118

14.

Design and testing of novel oncolytic vaccinia strains.

Thorne, Steve H.

Methods Mol Biol ; 542: 635-47, 2009.

Article in English | MEDLINE | ID: mdl-19565925

15.

Oncolytic vaccinia virus: from bedside to benchtop and back.

Thorne, Steve H.

Curr Opin Mol Ther ; 10(4): 387-92, 2008 Aug.

Article in English | MEDLINE | ID: mdl-18683104

16.

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.

Kirn, David H; Wang, Yaohe; Le Boeuf, Fabrice; Bell, John; Thorne, Steve H.

PLoS Med ; 4(12): e353, 2007 Dec.

Article in English | MEDLINE | ID: mdl-18162040

17.

Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.

Chan, John K; Hamilton, Chad A; Cheung, Michael K; Karimi, Mobin; Baker, Jeanette; Gall, Jonathan M; Schulz, Stephan; Thorne, Steve H; Teng, Nelson N; Contag, Christopher H; Lum, Lawrence G; Negrin, Robert S.

Clin Cancer Res ; 12(6): 1859-67, 2006 Mar 15.

Article in English | MEDLINE | ID: mdl-16551871

18.

Adding STING to the Tale of Oncolytic Virotherapy.

Thorne, Steve H.

Trends Cancer ; 2(2): 67-68, 2016 Feb 01.

Article in English | MEDLINE | ID: mdl-27004260

19.

Noninvasive Imaging of Fluorescent Reporters in Small Rodent Models Using Fluorescence Molecular Tomography.

Hou, Weizhou; Thorne, Steve H.

Methods Mol Biol ; 1444: 67-72, 2016.

Article in English | MEDLINE | ID: mdl-27283418

20.

Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy.

Hou, Weizhou; Sampath, Padma; Rojas, Juan J; Thorne, Steve H.

Cancer Cell ; 30(1): 108-119, 2016 07 11.

Article in English | MEDLINE | ID: mdl-27374223

Nursing VHL Search Portal

Information and Knowledge for Health

Config filters

Your selection (0)

Export format:

Export:

Oncolytic Virotherapy and the Tumor Microenvironment.

Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.

Virus fuels NK cell killing of leukemia.

Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases.

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

Differential biodistribution of oncolytic poxvirus administered systemically in an autochthonous model of hepatocellular carcinoma.

The initial phase of an immune response functions to activate regulatory T cells.

Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters.

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.

Enhancing biological therapy through conditional regulation of protein stability.

Role of nitric oxide in Salmonella typhimurium-mediated cancer cell killing.

Giving oncolytic vaccinia virus more BiTE.

CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy.

Design and testing of novel oncolytic vaccinia strains.

Oncolytic vaccinia virus: from bedside to benchtop and back.

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.

Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.

Adding STING to the Tale of Oncolytic Virotherapy.

Noninvasive Imaging of Fluorescent Reporters in Small Rodent Models Using Fluorescence Molecular Tomography.

Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy.